17th Sep 2015 07:00
LONDON (Alliance News) - Avacta Group PLC said Thursday it has appointed Mike Owen, formerly senior vice president and head of research at GlaxoSmithKline PLC's Biopharmaceuticals Research and Development unit, to its board as a non-executive director.
Avacta provides diagnostic tools and products for the life sciences market.
Owen is also an independent board member at Zealand Pharma AS, and non-executive director of Ossianix Inc and Blink Therapeutics.
"I am absolutely delighted that we have been able to attract someone with Mike's credentials to our board. His extensive experience in the field of novel biotherapeutic platforms will be invaluable as we progress development and commercialisation of Affimers as therapeutics. Additionally he brings with him considerable clinical and market knowledge as well as a broad network throughout the biopharmaceutical sector," said Avacta Chairman Trevor Nicholls in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta GroupGlaxosmithkline